P321 Cessation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn’s Disease: Individual Patient Data Meta-Analysis of 323 patients from 12 studies
Ten Bokkel Huinink, S.(1);van der Woude, J.(1);Casanova, M.J.(2);Bouguen, G.(3);Mak, J.W.Y.(4);Molnar, T.(5);Seidelin, J.(6);Aurelien, A.(7);D'Haens, G.(8);Riviere, P.(9);Guidi, L.(10);Renata, B.(5);Lin, W.C.(11);de Vries, A.(12);
(1)Erasmus Medical Center, Gastroenterology and hepatology, Amsterdam, The Netherlands;(2)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-IP- Universidad Autónoma de Madrid UAM and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology, Madrid, Spain;(3)University Hospital of Pontchaillou, Gastroenterology and Hepatology, Rennes, France;(4)Chinese University of Hong, Medicine and Therapeutics, Hong Kong, Hong Kong- China;(5)University of Szeged, First department of Medicine, Szeged, Hungary;(6)Herlev Hospital, Gastroenterology and Hepatology, Copenhagen, Denmark;(7)Henri Mondor Hospital- Assistance Publique-Hôpitaux de Paris APHP- Paris Est Creteil University UPEC, Gastroenterology, Creteil, France;(8)Amsterdam UMC- location AMC, Gastroenterology and Hepatology, Amsterdam, The Netherlands;(9)Hospitalier Universitaire, Gastroenterology and Hepatology, Bordeaux, France;(10)Università Cattolica del Sacro Cuore, Internal medicine, Rome, Italy;(11)Mackay Memorial Hospital, Gastroenterology and Hepatology, Taipei, Taiwan- Province Of China;(12)Erasmus MC, Gastroenterology and Hepatology, Rotterdam, The Netherlands
The risk of relapse after anti-tumour necrosis factor [TNF] therapy cessation in Crohn’s disease [CD] patients with perianal fistulas is unclear. We aimed to assess the risk of relapse after anti-TNF cessation in a large cohort and to identify risk factors.
A systemic literature search was conducted to identify cohort studies reporting on the incidence of relapse after cessation of anti-TNF therapy in CD patients. Individual patient data [IPD] were requested from the original study cohorts. Inclusion criteria for IPD-meta-analysis (IPD-MA) included age ³ 18 years, perianal fistulizing CD as indication for start of anti-TNF therapy, minimal treatment duration ³3 doses, and remission of luminal and perianal CD at cessation of anti-TNF therapy. Primary outcome was CD relapse [either perianal or luminal]. Perianal fistula relapse was defined as recurrence of draining perianal fistula related to previous or new fistula tracks, or abscess. Luminal relapse was defined as a clinical, biochemical, endoscopic, or radiological relapse requiring treatment or dose optimization of IBD medication or surgery. In a secondary analysis, risk factors associated with relapse were assessed using multivariate logistic regression analysis.
A total of 307 patients from 12 studies in 9 countries were included in this IPD-MA. The median duration of anti-TNF treatment prior to therapy cessation was 14 months [IQR 6.1 – 29.9]. In 272/307 patients [89%] anti-TNF therapy was started for active perianal fistula and in 34 [11%] for both active perianal fistula and luminal CD. 169 patients [55%] developed a relapse [either perianal or luminal] after a median follow-up after cessation of 25 months [IQR 12 – 54]. Overall cumulative incidence of relapse was 31% and 43% at 1 and 2 years after anti-TNF cessation. Risk factor for CD relapse include upper GI involvement (L4) [HR 1.9], whereas older age [A3 vs A1, HR 0.48] and continuation of concomitant immunomodulators [HR 0.62] were protective factors. For a subgroup of patients with active perianal fistula and in luminal remission at start of anti-TNF, the cumulative incidence relapse rates were 25% and 43% at 1 and 2 years. No considerable differences in risk factors were found within this subgroup regarding risk of recurrence. Of the 179 patients who relapsed, 104 were retreated with anti-TNF with a response rate of 85%.
According to this IPD-MA, approximately two-thirds of CD patients with perianal fistula remain in remission with regard to fistulizing and luminal disease during 2 years after cessation of anti-TNF therapy. Further risk stratification based on perianal fistula characteristics is required.